Cencora, Inc. (COR)
| Market Cap | 45.90B |
| Revenue (ttm) | 283.83B |
| Net Income (ttm) | 1.86B |
| Shares Out | 196.01M |
| EPS (ttm) | 9.21 |
| PE Ratio | 25.43 |
| Forward PE | 16.12 |
| Dividend | $2.04 (0.87%) |
| Ex-Dividend Date | Aug 9, 2024 |
| Volume | 760,873 |
| Open | 235.80 |
| Previous Close | 236.54 |
| Day's Range | 233.68 - 235.80 |
| 52-Week Range | 182.75 - 247.66 |
| Beta | 0.44 |
| Analysts | Buy |
| Price Target | 254.80 (+8.81%) |
| Earnings Date | Nov 6, 2024 |
About COR
Cencora, Inc. sources and distributes pharmaceutical products. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institu... [Read more]
Financial Performance
In 2023, Cencora's revenue was $262.17 billion, an increase of 9.89% compared to the previous year's $238.59 billion. Earnings were $1.75 billion, an increase of 2.74%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for COR stock is "Buy." The 12-month stock price forecast is $254.8, which is an increase of 8.81% from the latest price.
News
Cencora Announces Date and Time for Fourth Quarter Fiscal 2024 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2024 on Wednesday, November 6, 2024, prior to the op...
Cencora Supports Pharmaceutical Supply Chain Education with Two New Programs for Health System Pharmacy Residents
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora (formerly AmerisourceBergen), a global healthcare company, announced its two latest pharmacy education initiatives that are designed to equip health system ...
Cencora Elects Frank Clyburn to Its Board of Directors
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Frank Clyburn as a new independent director, effective October 1, 2024. With the e...
Intelliguard, Cencora Partner to Increase Compatibility of RFID-Tagged Medications, Medication Management Systems
SAN DIEGO & COLUMBUS, Ohio & DENVER--(BUSINESS WIRE)--Intelliguard, a fast-growing provider of medication management and data-intelligence solutions, announces an industry-transforming partnership wit...
Walgreens continues to shed stake in Cencora as it looks to bolster turnaround
Struggling drug-store chain Walgreens Boots Alliance Inc. has sold off shares of drug distributor Cencora Inc., handing the retailer some $1.1 billion in proceeds as it tries to carry out a turnaround...
Pharma giant Cencora is alerting millions about its data breach
Cencora has so far notified over a million people around the U.S. that their personal and protected health information was compromised in a data breach earlier this year, TechCrunch has found.
Walgreens further reduces stake in Cencora
Walgreens Boots Alliance said on Thursday it has sold shares in drug distributor Cencora for proceeds of about $1.1 billion.
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of ap...
Walgreens Boots Alliance Sells Shares of Cencora for Approximately $1.1 Billion of Proceeds
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold all of its remaining unencumbered shares of Cencora, Inc. (NYSE: COR) common stock pursu...
Cencora says additional data stolen in February cyberattack
U.S. drug distributor Cencora said on Wednesday additional data on patients, beyond what was initially identified, had been stolen in a cyberattack and data breach that happened in February.
Cencora, Inc. (COR) Q3 2024 Earnings Call Transcript
Cencora, Inc. (NYSE:COR) Q3 2024 Earnings Conference Call July 31, 2024 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President, Head of Investor Relations & Treasury Steve Collis - Ch...
Cencora raises annual profit forecast on strong demand for specialty medicines
Cencora raised its annual profit forecast again on Wednesday, driven by strong demand for high-priced specialty medicines that treat complex diseases such as cancer.
Cencora Reports Fiscal 2024 Third Quarter Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 third quarter ended June 30, 2024, revenue increased 10.9 percent year-over-year to $74.2 bill...
The Highest Quality Dividend Growth Stocks In 2024
This article updates one I wrote in August 2022, which was based on a template article by David Van Knapp published in June 2020. I use an adapted quality scoring system to assess the quality of divid...
Cencora Announces Date and Time for Third Quarter Fiscal 2024 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2024 on Wednesday, July 31, 2024, prior to the openin...
Cencora: Long-Term Compounder With Mouth-Watering Economics
COR shares have advanced 13% since my last publication, adding conviction to the long-term thesis. The company has exceptional economic characteristics with abnormally high ROICs and negative working ...
AmerisourceBergen Specialty Group Substitute Notice of Data Incident to Affected Individuals
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Specialty Group (ABSG) is issuing a substitute notice to individuals who may have been impacted by a data security incident. ABSG's parent company...
AmerisourceBergen Specialty Group Provides Substitute Notice of Data Incident to Affected Individuals
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Specialty Group, LLC (ABSG) is issuing notice to individuals who may have been impacted by a data security incident. ABSG's parent company previou...
Cencora notifies individuals about data stolen earlier this year
U.S. drug distributor Cencora has notified affected individuals that their personal and highly sensitive medical information was stolen during a cyberattack and data breach earlier this year, the comp...
Cencora to buy $400 million in stock back from Walgreens
Cencora has agreed to buy about $400 million in stock back from Walgreens Boots Alliance, the second time the pharmacy chain has reduced its stake in the company this year as it looks to free up cash ...
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance and Raises Fiscal 2024 Guidance
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of ap...
Walgreens Boots Alliance Sells Shares of Cencora for $400 Million of Proceeds
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of Cencora, Inc. (NYSE: COR) pursuant to a share repurchase by Cencora in the amo...
Cencora To Host Inaugural ThinkLive Cell and Gene Therapy Summit
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global healthcare company, will convene leaders from across the healthcare and biopharmaceutical industries for its inaugural ThinkLive Cell and Gene The...
Cencora, Inc. (COR) Q2 2024 Earnings Call Transcript
Cencora, Inc. (NYSE:COR) Q2 2024 Earnings Call Transcript May 1, 2024 8:30 AM ET Company Participants Bennett Murphy - SVP, Head of IR and Treasury Steve Collis - Chairman, President, and CEO Bob Mau...
Cencora beats profit estimates on strong demand for costly specialty drugs
Cencora beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for costly specialty medicines that treat complex diseases such as cancer and rheumatoid arthritis.